Silence Therapeutics (SLN) EBT Margin (2024 - 2026)
Silence Therapeutics (SLN) posted EBT Margin of 3544.31% for Q1 2026, up 89.76% sequentially from 34617.65% in Q4 2025, and up 1654724.0% YoY from N/an in Q1 2025.
Silence Therapeutics (SLN) EBT Margin (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported EBT Margin for 3 years, with the latest figure at 3544.31% in Q1 2026.
- Quarterly EBT Margin rose 1654724.0% year-over-year to 3544.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8942.55% (down 868692.0% YoY) and the FY2025 annual result came in at 15849.91%, down 1574712.0% from the prior year.
- EBT Margin rose to 3544.31% in Q1 2026 per SLN's latest filing, from 34617.65% in the prior quarter.
- Over five years, EBT Margin peaked at 49.9% in Q4 2024 and troughed at 34617.65% in Q4 2025.
- A 3-year average of 9823.87% and a median of 3544.31% in 2026 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2025 and 2026: EBT Margin slumped 3466754 bps in 2025, then soared 1654724 bps in 2026.
- Over 3 years, EBT Margin stood at 49.9% in 2024, then plunged by 69481 bps to 34617.65% in 2025, then soared by 90 bps to 3544.31% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 3544.31%, 34617.65%, and 13180.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,544.31% |
| Dec 31, 2025 | -34,617.65% |
| Sep 30, 2025 | -13,180.50% |
| Jun 30, 2025 | -12,207.14% |
| Mar 31, 2025 | -20,091.55% |
| Dec 31, 2024 | 49.90% |
| Sep 30, 2024 | -2,369.49% |
| Jun 30, 2024 | -2,440.88% |
| Mar 31, 2024 | -13.17% |